Medicus Pharma LTD. (MDCXW) — SEC Filings

Overview

Medicus Pharma LTD. (MDCXW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 8, 2025: Medicus Pharma Ltd. filed an 8-K on December 8, 2025, reporting on several key events. These include entering into a material definitive agreement, unregistered sales of equity securities, and Regulation FD disclosures. The filing also contains financial statements and exhibits related to these even

Sentiment Summary

Across 37 filings, the sentiment breakdown is: 4 bearish, 33 neutral. The dominant filing sentiment for Medicus Pharma LTD. is neutral.

Filing Type Overview

Medicus Pharma LTD. (MDCXW) has filed 23 8-K, 3 S-1, 3 10-Q, 1 8-K/A, 1 10-K/A, 1 10-K, 5 6-K with the SEC between Nov 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (37)

• 8-K Filing — 8-K · Dec 30, 2025
• Medicus Pharma Ltd. Files 8-K on Agreements & Equity Sales — 8-K · Dec 8, 2025 Risk: medium
  Medicus Pharma Ltd. filed an 8-K on December 8, 2025, reporting on several key events. These include entering into a material definitive agreement, unregistered
• Medicus Pharma Ltd. Files 8-K on Executive Changes — 8-K · Dec 1, 2025 Risk: medium
  Medicus Pharma Ltd. filed an 8-K on November 28, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certai
• Medicus Pharma S-1: Armistice Capital to Resell 2.68M Shares — S-1 · Nov 19, 2025 Risk: high
  Medicus Pharma Ltd. (MDCXW) filed an S-1 on November 19, 2025, primarily for the resale of up to 2,680,000 common shares by Armistice Capital Master Fund Ltd. u
• Medicus Pharma's Loss Quadruples Amid R&D Surge, Equity Dips to Deficit — 10-Q · Nov 14, 2025 Risk: high
  Medicus Pharma Ltd. (MDCXW) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $27,259,804, a substantial rise f
• Medicus Pharma Reports Unregistered Equity Sales — 8-K · Oct 17, 2025 Risk: medium
  Medicus Pharma Ltd. filed an 8-K on October 17, 2025, reporting unregistered sales of equity securities. The filing details the company's principal executive of
• Medicus Pharma S-1: Yorkville to Resell 7.5M Shares; Company Seeks $9.9M More — S-1 · Sep 29, 2025 Risk: high
  Medicus Pharma Ltd. (MDCXW) filed an S-1 on September 29, 2025, for the resale of up to 7,500,000 common shares by YA II PN, Ltd. (Yorkville), a selling shareho
• Medicus Pharma Ltd. Files 8-K for Material Agreement — 8-K · Sep 18, 2025 Risk: medium
  Medicus Pharma Ltd. announced on September 17, 2025, the entry into a material definitive agreement and the creation of a direct financial obligation. The compa
• Medicus Pharma Ltd. Reports Board and Officer Changes — 8-K · Sep 12, 2025 Risk: medium
  Medicus Pharma Ltd. announced on September 12, 2025, changes in its board and officer composition, including the departure of certain directors and officers, th
• Medicus Pharma Completes Acquisition, Appoints New Officers — 8-K · Sep 2, 2025 Risk: medium
  Medicus Pharma Ltd. announced on August 29, 2025, the completion of an acquisition, the departure of a director, and the appointment of new officers. The compan
• Medicus Pharma Ltd. Files 8-K on Equity Sales — 8-K · Aug 22, 2025 Risk: medium
  Medicus Pharma Ltd. filed an 8-K on August 22, 2025, reporting unregistered sales of equity securities and other events. The filing details the company's operat
• Medicus Pharma's Losses Widen Amid Aggressive Equity Raises — 10-Q · Aug 11, 2025 Risk: high
  Medicus Pharma Ltd. (MDCXW) reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, indicating its pre-rev
• Medicus Pharma Ltd. Files 8-K — 8-K · Aug 4, 2025 Risk: low
  Medicus Pharma Ltd. filed an 8-K on August 4, 2025, reporting other events and financial statements. The company is incorporated in Ontario and has its principa
• Medicus Pharma Ltd. Files 8-K Report — 8-K · Jul 30, 2025 Risk: low
  On July 29, 2025, Medicus Pharma Ltd. filed an 8-K report. The filing indicates that the company is incorporated in Ontario and has its principal executive offi
• Medicus Pharma Ltd. Files 8-K with Updates — 8-K · Jul 23, 2025 Risk: low
  Medicus Pharma Ltd. filed an 8-K on July 23, 2025, reporting on matters submitted to a vote of security holders and other events. The filing includes financial
• Medicus Pharma Ltd. Files 8-K: Material Agreement & Equity Sales — 8-K · Jul 14, 2025 Risk: medium
  On July 14, 2025, Medicus Pharma Ltd. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity securit
• Medicus Pharma Ltd. Files 8-K/A Amendment — 8-K/A · Jul 3, 2025 Risk: low
  Medicus Pharma Ltd. filed an amendment (8-K/A) on July 3, 2025, to its previous report dated June 29, 2025. This amendment pertains to financial statements and
• Medicus Pharma Ltd. Files 8-K for Material Agreement — 8-K · Jun 30, 2025 Risk: medium
  On June 29, 2025, Medicus Pharma Ltd. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial stateme
• Medicus Pharma Ltd. Files 8-K: Director & Officer Changes — 8-K · Jun 23, 2025 Risk: medium
  On June 23, 2025, Medicus Pharma Ltd. filed an 8-K report detailing changes in its board of directors and executive officers, along with updates on compensatory
• Medicus Pharma Ltd. Files 8-K for Material Agreement — 8-K · Jun 20, 2025 Risk: medium
  On June 17, 2025, Medicus Pharma Ltd. entered into a material definitive agreement, creating a direct financial obligation. The company, headquartered at 300 Co
• Medicus Pharma Appoints Marcum LLP as New Auditor — 8-K · Jun 5, 2025 Risk: low
  Medicus Pharma Ltd. announced on June 3, 2025, a change in its certifying accountant. The company has appointed Marcum LLP as its new independent registered pub
• Medicus Pharma Ltd. Files 8-K for Material Agreement & Equity Sale — 8-K · Jun 2, 2025 Risk: medium
  Medicus Pharma Ltd. announced on May 29, 2025, the entry into a material definitive agreement and unregistered sales of equity securities. The company is involv
• Medicus Pharma Files S-1 for Continuous Offering — S-1 · May 27, 2025 Risk: medium
  Medicus Pharma Ltd. (MDCXW) filed an S-1 registration statement on May 27, 2025, for a delayed or continuous offering of securities under Rule 415. The company,
• Medicus Pharma Ltd. Files Q1 2025 10-Q — 10-Q · May 12, 2025 Risk: medium
  Medicus Pharma Ltd. filed its Form 10-Q for the period ending March 31, 2025. The company, located at 300 Conshohocken State Rd., Suite 200, W. Conshohocken, PA
• Medicus Pharma Ltd. Files 8-K for Material Agreement — 8-K · May 5, 2025 Risk: medium
  Medicus Pharma Ltd. announced on May 2, 2025, that it entered into a material definitive agreement. This filing also indicates the creation of a direct financia
• Medicus Pharma Ltd. Files 2024 Annual Report Amendment — 10-K/A · Apr 30, 2025 Risk: low
  Medicus Pharma Ltd. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, incorporated in Ontario, Canada,
• Medicus Pharma Ltd. Files 8-K — 8-K · Apr 28, 2025 Risk: low
  Medicus Pharma Ltd. filed an 8-K on April 28, 2025, reporting other events and financial statements as of April 26, 2025. The company, incorporated in Ontario w
• Medicus Pharma Ltd. Files 2024 10-K — 10-K · Mar 28, 2025 Risk: medium
  Medicus Pharma Ltd. filed its 2024 10-K on March 28, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, operat
• Medicus Pharma Ltd. Files 8-K — 8-K · Mar 25, 2025 Risk: low
  Medicus Pharma Ltd. filed an 8-K on March 25, 2025, reporting other events and financial statements as of March 21, 2025. The company, incorporated in Ontario w
• Medicus Pharma Ltd. Files 8-K — 8-K · Mar 20, 2025 Risk: low
  Medicus Pharma Ltd. filed an 8-K on March 20, 2025, reporting other events and financial statements as of March 18, 2025. The company, incorporated in Ontario w
• Medicus Pharma Ltd. Files 8-K: Material Agreement & Equity Sales — 8-K · Mar 11, 2025 Risk: medium
  Medicus Pharma Ltd. announced on March 6, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity
• Medicus Pharma Ltd. Files 8-K: Material Agreement & Equity Sales — 8-K · Feb 11, 2025 Risk: medium
  On February 10, 2025, Medicus Pharma Ltd. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
• Medicus Pharma Ltd. Changes Auditor — 6-K · Dec 26, 2024 Risk: low
  Medicus Pharma Ltd. filed a Form 6-K on December 26, 2024, reporting a change in its auditor. The filing includes a Notice of Change of Auditor, a letter from t
• Medicus Pharma Ltd. Files 6-K Report — 6-K · Dec 12, 2024 Risk: low
  Medicus Pharma Ltd. filed a Form 6-K on December 12, 2024, to report a press release dated the same day. The company, incorporated in A6 with its principal exec
• Medicus Pharma Ltd. Files 6-K Report — 6-K · Dec 2, 2024 Risk: low
  Medicus Pharma Ltd. filed a Form 6-K on December 2, 2024, to report a press release dated the same day. The company, incorporated in Canada and operating in the
• Medicus Pharma Ltd. Files 6-K with Q3 Financials — 6-K · Nov 25, 2024 Risk: low
  Medicus Pharma Ltd. filed a Form 6-K on November 25, 2024, reporting on its financial performance for the three and nine months ended September 30, 2024. The fi
• Medicus Pharma Ltd. Files November 2024 6-K Report — 6-K · Nov 18, 2024 Risk: low
  Medicus Pharma Ltd. filed a Form 6-K on November 18, 2024, reporting for the month of November 2024. The filing indicates the company's principal executive offi

Risk Profile

Risk Assessment: Of MDCXW's 36 recent filings, 4 were flagged as high-risk, 18 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Medicus Pharma LTD.'s most recent 10-Q filing (Nov 14, 2025):

• Net Income: -$27,259,804
• EPS: -$1.91
• Cash Position: $8,662,091
• Total Assets: $9,977,661
• Total Debt: $6,785,812

Key Executives

• Dr. Raza Bokhari
• Christopher J. Cummings
• Aaron Sonshine
• Raza Bokhari

Industry Context

Medicus Pharma operates in the highly competitive and capital-intensive biopharmaceutical industry. As a clinical-stage company, it faces intense competition from larger, established pharmaceutical companies and numerous other biotech firms vying for market share and regulatory approval. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles, with success often dependent on innovation and effective clinical trial execution.

Top Tags

material-agreement (9) · filing (9) · equity-sale (7) · financials (6) · pharmaceutical (5) · regulatory-filing (4) · 8-K (4) · S-1 Filing (3) · Clinical Stage (3) · Biotech (3)

Key Numbers

• SIC Code: 2834 — Standard Industrial Classification for Pharmaceutical Preparations
• SEC File Number: 001-42408 — Identifies the company's filing with the SEC.
• IRS Employer ID Number: 98-1778211 — Company's tax identification number.
• Common Shares: 2,680,000 — Maximum number of common shares Armistice Capital may sell
• Private Warrant Exercise Price: $3.75 — Exercise price for each Private Warrant held by Armistice Capital
• Private Warrant Expiration: July 15, 2030 — Expiration date for the Private Warrants
• Accumulated Deficit: $56.2 million — Total accumulated deficit as of September 30, 2025, indicating lack of profitability
• Antev Acquisition Stake: 98.6% — Percentage of Antev Limited shares acquired by Medicus Pharma in August 2025
• MDCX Closing Price: $2.14 — Closing price of Medicus Pharma common shares on November 18, 2025
• MDCXW Closing Price: $0.95 — Closing price of Medicus Pharma public warrants on November 18, 2025
• Net Loss (9 months ended Sep 30, 2025): $27,259,804 — Increased from $7,618,964 in 2024, indicating a significant increase in losses.
• Total Operating Expenses (9 months ended Sep 30, 2025): $26,568,702 — Increased from $7,595,453 in 2024, primarily due to IPR&D and G&A.
• In-Process Research and Development (IPR&D) - Teverelix: $8,717,475 — New expense in 2025, contributing significantly to operating losses.
• General and Administrative Expenses (9 months ended Sep 30, 2025): $12,720,666 — Increased from $5,432,773 in 2024, showing higher overhead.
• Cash and Cash Equivalents (Sep 30, 2025): $8,662,091 — Increased from $4,164,323 at Dec 31, 2024, due to financing activities.

Related Companies

MDX · MDCX · MDXC

Frequently Asked Questions